Analysts See $-0.04 EPS for Marrone Bio Innovations, Inc. (MBII)

July 14, 2018 - By Mary Gaskins

Marrone Bio Innovations, Inc. (NASDAQ:MBII) LogoInvestors sentiment increased to 5.5 in Q1 2018. Its up 4.93, from 0.57 in 2017Q4. It improved, as 1 investors sold Marrone Bio Innovations, Inc. shares while 1 reduced holdings. 6 funds opened positions while 5 raised stakes. 78.12 million shares or 565.72% more from 11.74 million shares in 2017Q4 were reported.
Geode Cap Mgmt Limited Liability, a Massachusetts-based fund reported 89,410 shares. Ogorek Anthony Joseph New York Adv accumulated 0% or 300 shares. Guggenheim Ltd Liability holds 17,851 shares or 0% of its portfolio. Primecap Mgmt Ca invested in 0% or 2.63M shares. Hanson Mcclain Incorporated has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). 24.71M were reported by Waddell Reed Financial. Blackrock holds 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII) or 77,806 shares. Northern Trust stated it has 31,936 shares. State Street Corp holds 0% or 10,800 shares. Savings Bank Of America De invested in 0% or 10,102 shares. Carroll Fin Assocs holds 0% or 2,000 shares in its portfolio. Bluecrest Cap Mgmt Ltd holds 0% or 12,428 shares. Barclays Public Limited Com has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Capital Planning Advisors Ltd has 0.02% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 33,079 shares. Ardsley Advisory reported 10.35M shares or 1.91% of all its holdings.

Since February 5, 2018, it had 1 buying transaction, and 0 insider sales for $5.00 million activity.

Analysts expect Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report $-0.04 EPS on August, 13.They anticipate $0.21 EPS change or 84.00 % from last quarter’s $-0.25 EPS. After having $-0.04 EPS previously, Marrone Bio Innovations, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.52% or $0.01 during the last trading session, reaching $1.92. About 174,618 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 48.33% since July 14, 2017 and is uptrending. It has outperformed by 35.76% the S&P500.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $212.10 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

More important recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Globenewswire.com which released: “Marrone Bio Innovations Joins the Russell 2000 Index” on June 25, 2018, also Nasdaq.com published article titled: “Marrone Bio Innovations to Host Virtual Roadshow Webinar on July 26th, 2018”, Investorideas.com published: “(NASDAQ: $MBII) News: Grandevo® CG and Venerate® CG for Pest Insect and Mite Control Cleared for Use on …” on June 28, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) was released by: Bizjournals.com and their article: “Why Marrone Bio is sponsoring a cannabis-growing competition” with publication date: June 20, 2018.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: